Company intelligence / Profile preview

ADvantage Therapeutics

Miami, Florida, USAadvantagetherapeutics.com ↗

Ownership: Private
Development stage: Phase 2

Overview

The company's lead compound AD04™ is in confirmatory Phase 2b clinical trials in Europe and the UK for early Alzheimer's Disease patients. In previous trials, AD04™ demonstrated statistically significant slower decline in cognitive and quality of life clinical measures compared to other treatment groups, as well as slower decline in hippocampal volume as a biomarker.

Therapeutic areas: OtherNeurology
Modalities: ImmunomodulatorKlotho protein therapies
Industry: Biotech

Drug pipeline

5 assets

AL04

Preclinical

4 more assets in the full pipeline.

Request access →

Partnerships

Longevitytech.fund

Beyond the preview

Go deeper on ADvantage Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ADvantage Therapeutics.

Explore the full profile